Ontology highlight
ABSTRACT:
SUBMITTER: Lee JC
PROVIDER: S-EPMC3710966 | biostudies-literature | 2013 Jun
REPOSITORIES: biostudies-literature
Lee Jae Cheol JC Jang Seung Hun SH Lee Kye Young KY Kim Young-Chul YC
Cancer research and treatment 20130630 2
Since the first description of non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutation as a distinct clinical entity, studies have proved EGFR tyrosine kinase inhibitors (TKIs) as a first choice of treatment. The median response duration of TKIs as a first-line treatment for EGFR mutant tumors ranges from 11 to 14 months. However, acquired resistance to EGFR-TKIs is inevitable due to various mechanisms, such as T790M, c-Met amplification, activation of ...[more]